Summary of disease and stage risk groups from original DRI
| Disease . | Disease risk . | |
|---|---|---|
| AML favorable cytogenetics | Low | |
| CLL | ||
| CML | ||
| Indolent B-cell NHL | ||
| ALL | Intermediate | |
| AML intermediate cytogenetics | ||
| MDS intermediate cytogenetics | ||
| Myeloproliferative neoplasms | ||
| Multiple myeloma | ||
| HL | ||
| DLBCL/transformed indolent B-cell NHL | ||
| Mantle cell lymphoma | ||
| Low-risk T-cell lymphoma | ||
| AML adverse cytogenetics | High | |
| MDS adverse cytogenetics | ||
| High-risk T-cell lymphoma | ||
| Stage | Stage risk | |
| Any CR | Low | |
| PR (including improved but <CR MDS/MPN) | ||
| Untreated | ||
| Chronic phase CML | ||
| Induction failure | High | |
| Active relapse | ||
| Accelerated or blast phase CML | ||
| Overall assignment | ||
| Disease risk | Stage risk | DRI assignment |
| Low | Low | Low |
| Low | High | Intermediate |
| Intermediate | Low | |
| Intermediate | High | High |
| High | Low | |
| High | High | Very high |
| Disease . | Disease risk . | |
|---|---|---|
| AML favorable cytogenetics | Low | |
| CLL | ||
| CML | ||
| Indolent B-cell NHL | ||
| ALL | Intermediate | |
| AML intermediate cytogenetics | ||
| MDS intermediate cytogenetics | ||
| Myeloproliferative neoplasms | ||
| Multiple myeloma | ||
| HL | ||
| DLBCL/transformed indolent B-cell NHL | ||
| Mantle cell lymphoma | ||
| Low-risk T-cell lymphoma | ||
| AML adverse cytogenetics | High | |
| MDS adverse cytogenetics | ||
| High-risk T-cell lymphoma | ||
| Stage | Stage risk | |
| Any CR | Low | |
| PR (including improved but <CR MDS/MPN) | ||
| Untreated | ||
| Chronic phase CML | ||
| Induction failure | High | |
| Active relapse | ||
| Accelerated or blast phase CML | ||
| Overall assignment | ||
| Disease risk | Stage risk | DRI assignment |
| Low | Low | Low |
| Low | High | Intermediate |
| Intermediate | Low | |
| Intermediate | High | High |
| High | Low | |
| High | High | Very high |
For this study, patients in first and subsequent PR were grouped and assigned to low risk regardless of conditioning intensity. BL was excluded from the cohort for this validation because it was not included in the original DRI.
DLBCL, diffuse large B-cell lymphoma; MPN, myeloproliferative neoplasms.